Ariad to co-promote ridaforolimus as partner Merck moves towards NDA
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals has exercised its option under its partnership with Merck & Co to co-promote the investigational mTOR inhibitor ridaforolimus in sarcoma upon its potential approval in the US and a launch in 2012.